Special Issue

Identifying Mechanisms and Patterns in Cardiovascular Disease

Message from the Guest Editor

Despite significant progress in the prevention and management of heart disease, there are always new emerging concepts, mechanistic understanding in atrial fibrillation, cardiomyopathy, cardiac hypertrophy, heart failure, and aortic and carotid stiffness. These new targets, biomarkers, or pathology processes may challenge or complement current or existing therapies. Future identification of device and therapeutic targets requires clinical insights as to how they may benefit the individual patient and align with current therapies. Holistically, we have rarely considered the immune system and its role in sustaining or driving cardiac disease. COVID has certainly been an interesting case for how immune dysregulation may also increase the burden of heart disease. This focused series considers emerging cardiovascular mechanistic pathways and associations, as well as how any newly identified target or mechanism of disease may fit into the realm of future clinical practice with particular emphasis on the individual patient.

Guest Editor

Prof. Dr. Craig Steven McLachlan

Centre for Healthy Futures, Torrens University Australia, Pyrmont, NSW 2009, Australia

Deadline for manuscript submissions

closed (31 January 2025)



Journal of Cardiovascular Development and Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/148618

Journal of Cardiovascular Development and Disease Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 icdd@mdpi.com

mdpi.com/journal/ jcdd





Journal of Cardiovascular Development and Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed





Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (*JCDD*, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand

National Heart & Lung Institute, Imperial College London, South Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) / CiteScore - Q2 (General Pharmacology, Toxicology and Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

